middle.news
Amplia Therapeutics Advances Narmafotinib with Phase 2b Daily Dosing Trial in Pancreatic Cancer
8:18am on Tuesday 19th of May, 2026 AEST
•
Healthcare
Read Story
Amplia Therapeutics Advances Narmafotinib with Phase 2b Daily Dosing Trial in Pancreatic Cancer
8:18am on Tuesday 19th of May, 2026 AEST
Key Points
Phase 2b trial explores daily dosing of narmafotinib
Combination with gemcitabine and Abraxane in advanced pancreatic cancer
Trial design aligned with FDA guidance
Enrollment to start in Q4 2026 across Australian sites
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE